Global Markets Direct's, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with latest updates, and special features on late-stage and discontinued projects. https://www.reportscorner.com/reports/23245/H5N1-Infection-(Avian-Influenza)-%E2%80%93-Pipeline-Review,-H1-2013/

1. RC
Reports Corner
H5N1 Infection (Avian Influenza) – Pipeline
Review, H1 2013

2. DescriptionDescription
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'H5N1 Infection (Avian Influenza) -
Pipeline Review, H1 2013', provides an overview of the
indication's therapeutic pipeline. This report provides information
on the therapeutic development for H5N1 Infection (Avian
Influenza), complete with latest updates, and special features on
late-stage and discontinued projects.

3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'H5N1 Infection (Avian Influenza) -
Pipeline Review, H1 2013', provides an overview of the
indication's therapeutic pipeline. This report provides information
on the therapeutic development for H5N1 Infection (Avian
Influenza), complete with latest updates, and special features on
late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for H5N1 Infection (Avian
Influenza). H5N1 Infection (Avian Influenza) - Pipeline Review, Half
Year is built using data and information sourced from Global
Markets Direct's proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third
party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated
disease.

4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Scope
- A snapshot of the global therapeutic scenario for H5N1 Infection
(Avian Influenza).
- A review of the H5N1 Infection (Avian Influenza) products under
development by companies and universities/research institutes
based on information derived from company and industry-specific
sources.
- Coverage of products based on various stages of development
ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
- Coverage of the H5N1 Infection (Avian Influenza) pipeline on the
basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Reasons to buy
- Identify and understand important and diverse types of
therapeutics under development for H5N1 Infection (Avian
Influenza).
- Identify emerging players with potentially strong product
portfolio and design effective counter-strategies to gain
competitive advantage.
- Plan mergers and acquisitions effectively by identifying players
of the most promising pipeline.
- Devise corrective measures for pipeline projects by
understanding H5N1 Infection (Avian Influenza) pipeline depth and
focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope.
.

6. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline.

7. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
H5N1 Infection (Avian Influenza) Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for H5N1 Infection (Avian Influenza) 10
H5N1 Infection (Avian Influenza) Therapeutics under Development by Companies 12
H5N1 Infection (Avian Influenza) Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18

8. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
H5N1 Infection (Avian Influenza) Therapeutics – Products under Development by Companies 21
H5N1 Infection (Avian Influenza) Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in H5N1 Infection (Avian Influenza) Therapeutics Development 26
GlaxoSmithKline plc 26
Inovio Biomedical Corporation 27
Daiichi Sankyo Company, Ltd 28
Emergent BioSolutions Inc. 29
Generex Biotechnology Corporation 30
Celltrion, Inc. 31
Nanotherapeutics, Inc. 32
Novartis AG 33

9. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Vertex Pharmaceuticals Incorporated 34
CEL-SCI Corporation 35
OPKO Health, Inc. 36
Hemispherx Biopharma, Inc. 37
Intercell AG 38
Medicago Inc. 39
NanoViricides, Inc. 40
Medigen Biotechnology Corp. 41
CytoGenix, Inc. 42
XOMA Ltd. 43
Green Cross Corporation 44
Antigen Express, Inc. 45
Colby Pharmaceutical Company 46
LigoCyte Pharmaceuticals, Inc. 47
Adimmune Corporation 48

10. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
TechnoVax, Inc. 49
MacroGenics, Inc. 50
AlphaVax, Inc. 51
Vaxin, Inc. 52
REPLICor Inc. 53
Protein Sciences Corporation 54
VaxInnate Corporation 55
Obio Pharmaceutical Holdings Limited. 56
Canopus BioPharma Incorporated 57
iBio, Inc. 58
Sirnaomics, Inc. 59
ImmuneRegen BioSciences, Inc. 60
Inviragen, Inc. 61
PaxVax 62

11. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Denka Seiken Co., Ltd. 63
H5N1 Infection (Avian Influenza) – Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
Homspera - Drug Profile 70
Flu Vaccine - Drug Profile 72
GelVac - Drug Profile 73
rintatolimod - Drug Profile 74
CEL-1000 - Drug VGX-3400X - Drug Profile 77
interferon alfa-n3 injection + interferon alfa-n3 low dose oral - Drug Profile 78
Pandemic Influenza Vaccine Patch - Drug Profile 79
REP-9-AC - Drug Profile 81

12. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
H5N1 Vaccine - Drug Profile 83
Vaccine For Pandemic Influenza (H1 & H5) - Drug Profile 85
PanBlok - Drug Profile 86
PanBlok - Drug Profile 88
PanBlok - Drug Profile 90
TG-21 - Drug Profile 92
Influenza Vaccine - Drug Profile 93
Aflunov - Drug Profile 95
H5N1 FCC Vaccine - Drug Profile 97
GSK-2340273A - Drug Profile 98
STP-702 - Drug Profile 101
VRC-AVIDNA036-00-VP - Drug Profile 102
F-10 Antibody Program - Drug Profile 103
TVX-003 - Drug Profile 104
CYDBA-507 - Drug Profile 105

13. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
(statin + caffeine) - Drug Profile 106
Influenza VLP vaccine - Drug Profile 107
MVA-H5HA - Drug Profile 108
Mult. mAbs/DARTs - Drug Profile 109
AE-AI Vaccine - Drug Profile 110
GSK-2590066A - Drug Profile 111
TMB-571 - Drug Profile 112
Flu Pandemic Vaccine - Drug Profile 113
GSK-1557484A - Drug Profile 115
Pandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) - Drug Profile 117
Flufirvitide-3 - Drug Profile 118
Anti-H5HA mAB - Drug Profile 119
H5N1 Avian Influenza Vaccine - Drug Profile 120
JVRS-100 + Pandemic Flu Vaccine - Drug Profile 122
PXVX-0103 - Drug Profile 124

14. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
MG-1109 - Drug Profile 125
INO-3510 - Drug Profile 127
INO-3401 - Drug Profile 129
AE-443p - Drug Profile 131
INO-3605 - Drug Profile 132
INO-3609 - Drug Profile 134
NV-INF-1 - Drug Profile 136
Avian Influenza Vaccine - Drug Profile 138
VAX-161 - Drug Profile 139
VX-787 - Drug Profile 140
Avian Flu Vaccine - Drug Profile 141
H5N1 Avian Influenza VLP vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 142
VAX161-01C - Drug Profile 144
AT-301 - Drug Profile 145
H5N1 Project - Drug Profile 146

15. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
KIB-PCI - Drug Profile 147
Chimigen Influenza Vaccine - Drug Profile 148
Antibody Against Avian Flu Virus - Drug Profile 149
rAd-04wtHA Vaccine - Drug Profile 150
rAd-04optHA Vaccine - Drug Profile 151Profile 75
rAd-04optHA + rAd-97optHA vaccine - Drug Profile 152
GP-1002 - Drug Profile 153
GREFLU/VIE - Drug Profile 154
H5N1 Infection (Avian Influenza) Therapeutics – Drug Profile Updates 155
H5N1 Infection (Avian Influenza) Therapeutics – Discontinued Products 173
H5N1 Infection (Avian Influenza) Therapeutics - Dormant Products 174
H5N1 Infection (Avian Influenza) – Product Development Milestones 176
Featured News & Press Releases 176
Appendix 184
Methodology 184

16. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Coverage 184
Secondary Research 184
Primary Research 184
Expert Panel Validation 184
Contact Us 185
Disclaimer 185

17. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/23245/H5N1-Infection-(Avian-Influenza)-
%E2%80%93-Pipeline-Review,-H1-2013/

18. Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com